Xu, W. , Xing, X. and Cheng, S. (2025) Urine-Based Liquid Biopsy for Detecting Recurrence of Bladder Cancer. International ...

Johnson & Johnson announced today that new data from the investigational Cohort 4 of the Phase 2b SunRISe-1 study show treatment with gemcitabine intravesical system resulted in high one-year ...

Johnson & Johnson's Inlexzo shows promising survival rates in BCG-unresponsive NMIBC patients. Read more here.

Johnson & Johnson (NYSE:JNJ) announced today that new data from the investigational Cohort 4 of the Phase 2b SunRISe-1 study show treatment with gemcitabine intravesical system resulted in high ...

This Research Topic seeks to tackle the pressing issue of variability in pathology practices concerning radical cystectomy (RC) specimens. Despite existing ...

British researchers have discovered that the virus can specifically trigger DNA damage in tissue in the bladder.

The U.S. Food and Drug Administration has approved Pfizer's Padcev (enfortumab vedotin-ejfv), a Nectin-4 directed ...

Gene Holdings Inc. , a clinical-stage, non-viral genetic medicines company, today announced that the U.S. Food and Drug Administration (FDA) has selected detalimogene voraplasmid (also known as ...

Astellas Pharma Inc. (ALPMY, 4503.T) announced that the European Medicines Agency (EMA) has validated for review a Type II variation application for PADCEV (enfortumab vedotin).

The FDA has approved pembrolizumab (Keytruda) or pembrolizumab Qlex with enfortumab vedotin (Padcev) as the first perioperative regimen for cisplatin-ineligible muscle-invasive bladder cancer. In the ...